September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more
Graybug Vision, a Phase 2 biotech developing long-acting formulations of drugs for ocular diseases, raised $90 million by offering 5.6 million shares at $16, the midpoint of the $15 to $17 range. The company originally filed to sell 4.7 million shares, before...read more
Graybug Vision, a Phase 2 biotech developing transformative medicines for ocular diseases, announced terms for its IPO on Monday.
The Redwood City, CA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At...read more
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more
US IPO Weekly Recap: Health and tech dominate the calendar in an 11 IPO week
September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings. Prescription drug price comparison platform GoodRx...read more
Wet AMD drug developer Graybug Vision prices upsized IPO at $16 midpoint
Graybug Vision, a Phase 2 biotech developing long-acting formulations of drugs for ocular diseases, raised $90 million by offering 5.6 million shares at $16, the midpoint of the $15 to $17 range. The company originally filed to sell 4.7 million shares, before...read more
Ocular disease biotech Graybug Vision sets terms for $75 million IPO
Graybug Vision, a Phase 2 biotech developing transformative medicines for ocular diseases, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At...read more
US IPO Weekly Recap: The September IPO market kicks off with a quiet week
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more